Catalent, Inc. Reports Third Quarter Fiscal 2022 Results

Catalent, Inc. сообщает результаты за третий квартал 2022 финансового года

Q3'22 net revenue of $1.27 billion increased 21% as reported, or 23% in constant currency, compared to Q3'21. Organic, constant-currency net revenue grew 20%, compared to Q3'21.

Q3'22 net earnings of $141 million.

Q3'22 Adjusted EBITDA(1) of $339 million increased 24% as reported, or 26% in constant currency, compared to Q3'21.

Increasing and tightening FY'22 guidance to reflect projected net revenue growth of 20-23% and Adjusted EBITDA growth of 24-28%, compared to previous projected net revenue growth of 19-22% and Adjusted EBITDA growth of 23-27%.

Preliminary FY'23 organic, constant-currency net revenue growth outlook in line with long-term 8-10% growth rate.

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced financial results for the third quarter of fiscal 2022, which ended March 31, 2022.

“We are pleased with our strong results in the third quarter and our plans to continue to expand our capabilities to address long-term customer needs as our end markets grow. Our recent acquisitions in cell therapy in the U.S. and biologics manufacturing in the U.K., as well as the recently approved $350 million investment in Bloomington, Indiana, will provide additional flexible capacity and allow us to deliver an increasing number of products and treatments to patients and consumers worldwide,” said John Chiminski, Chair and Chief Executive Officer of Catalent, Inc.

Third Quarter 2022 Consolidated Results

Net revenue of $1.27 billion increased 21% as reported, or 23% in constant currency, from the $1.05 billion reported for the third quarter a year ago. Overall organic net revenue growth (i.e., excluding the effect of acquisitions, divestitures, and currency translation) was 20% over the same periods.

Net earnings attributable to common shareholders were $141 million, or $0.78 per basic and $0.78 per diluted share, compared to net earnings attributable to common shareholders of $217 million, or $1.27 per basic share, $1.26 per diluted share, in the third quarter a year ago, the decrease driven in part by a $184 million gain from the sale of the Blow-Fill-Seal business in the prior-year period.

EBITDA from operations(1) was $308 million, a decrease of $112 million from $420 million in the third quarter a year ago, driven in part by a $184 million gain from sale of the Blow-Fill-Seal business in the prior-year period. Third quarter fiscal 2022 Adjusted EBITDA(1) was $339 million, or 27% of net revenue, compared to $274 million, or 26% of net revenue, in the third quarter a year ago. This represents an increase of 24% as reported and an increase of 26% on a constant-currency basis, compared to the fiscal 2021 period.

Adjusted Net Income(1) was $188 million, or $1.04 per diluted share, compared to Adjusted Net Income of $148 million, or $0.82 per diluted share, in the third quarter a year ago.

Third Quarter 2022 Segment Review

Balance Sheet and Liquidity

As of March 31, 2022, Catalent had $4.19 billion in total debt, and $3.31 billion in total debt net of cash, cash equivalents, and marketable securities, compared to $3.31 billion in total net debt as of December 31, 2021. The current debt structure does not include any significant maturity until 2027.

Catalent’s net leverage ratio(1) as of March 31, 2022 was 2.6x, compared to a proforma calculation of 2.8x at December 31, 2021 and 2.3x at March 31, 2021.

Fiscal Year 2022 Outlook

Fiscal Year 2023

Catalent projects organic, constant-currency net revenue growth for fiscal 2023, compared to fiscal 2022, in line with its previously announced range of long-term net revenue growth of 8-10%, due, in part, to its projection of strong commercial demand for products other than COVID-19 products and increased utilization of both current and recently acquired assets. This fiscal 2023 outlook mitigates future risk by assuming a considerable decline in COVID-19 product net revenue.

Earnings Webcast

The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET today. Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com. A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast. The webcast replay, along with the supplemental slides, will be available for 90 days in the “Investors” section of Catalent’s website at www.catalent.com.

About Catalent, Inc.

Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world.

With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is the industry’s preferred partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of nearly 7,000 products to over 1,000 customers annually.

Catalent’s expert workforce exceeds 19,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com.

Non-GAAP Financial Measures

Use of EBITDA from operations, Adjusted EBITDA, Adjusted Net Income and Segment EBITDA

Management measures operating performance based on consolidated earnings from operations before interest expense, expense (benefit) for income taxes, and depreciation and amortization, adjusted for the income or loss attributable to non-controlling interests (“EBITDA from operations”). EBITDA from operations is not defined under U.S. GAAP, is not a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP, and is subject to important limitations.

Catalent believes that the presentation of EBITDA from operations enhances an investor’s understanding of its financial performance. Catalent believes this measure is a useful financial metric to assess its operating performance across periods by excluding certain items that it believes are not representative of its core business and uses this measure for business planning purposes.

In addition, given the significant investments that Catalent has made in the past in property, plant and equipment, depreciation and amortization expenses represent a meaningful portion of its cost structure. Catalent believes that EBITDA from operations will provide investors with a useful tool for assessing the comparability between periods of Catalent's ability to generate cash from operations sufficient to pay taxes, to service debt and to undertake capital expenditures because it eliminates depreciation and amortization expense. Catalent presents EBITDA from operations in order to provide supplemental information that it considers relevant for the readers of its consolidated financial statements, and such information is not meant to replace or supersede U.S. GAAP measures. Catalent’s definition of EBITDA from operations may not be the same as similarly titled measures used by other companies.

Catalent evaluates the performance of its segments based on segment earnings before non-controlling interest, other (income) expense, impairments, restructuring costs, interest expense, income tax expense (benefit), and depreciation and amortization (“segment EBITDA”). Moreover, under Catalent’s credit agreement, its ability to engage in certain activities, such as incurring certain additional indebtedness, making certain investments and paying certain dividends, is tied to ratios based on Adjusted EBITDA, which is not defined under U.S. GAAP, is not a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP, and is subject to important limitations. Adjusted EBITDA is the covenant compliance measure used in the credit agreement governing debt incurrence and restricted payments. Because not all companies use identical calculations, Catalent’s presentation of Adjusted EBITDA may not be comparable to similarly titled measures of other companies.

Management also measures operating performance based on Adjusted Net Income and Adjusted Net Income per share. Adjusted Net Income is not defined under U.S. GAAP, is not a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP and is subject to important limitations. Catalent believes that the presentation of Adjusted Net Income and Adjusted Net Income per share enhances an investor’s understanding of its financial performance. Catalent believes these measures are a useful financial metric to assess its operating performance across periods by excluding certain items that it believes are not representative of its core business and Catalent uses these measures for business planning purposes. Catalent defines Adjusted Net Income as net earnings adjusted for amortization attributable to purchase accounting and adjustments for other cash and non-cash items included in the table below, partially offset by its estimate of the tax effects of such cash and non-cash items. Catalent believes that Adjusted Net Income and Adjusted Net Income per share provides investors with a useful tool for assessing the comparability between periods of its ability to generate cash from operations available to its stockholders. Catalent’s definition of Adjusted Net Income may not be the same as similarly titled measures used by other companies.

The most directly comparable U.S. GAAP measure to EBITDA from operations, Adjusted EBITDA, and Adjusted Net Income is net earnings. Included in this release is a reconciliation of net earnings to EBITDA from operations, Adjusted EBITDA and Adjusted Net Income.

Catalent does not provide a reconciliation of forward-looking non-GAAP financial measures to their comparable U.S. GAAP financial measures because it could not do so without unreasonable effort due to the unavailability of the information needed to calculate reconciling items and due to the variability, complexity and limited visibility of the adjusting items that would be excluded from the non-GAAP financial measures in future periods. When planning, forecasting, and analyzing future periods, Catalent does so primarily on a non-GAAP basis without preparing a U.S. GAAP analysis as that would require estimates for various cash and non-cash reconciling items that would be difficult to predict with reasonable accuracy. For example, equity compensation expense would be difficult to estimate because it depends on Catalent’s future hiring and retention needs, as well as the future fair market value of its common stock, all of which are difficult to predict and subject to constant change. It is equally difficult to anticipate the need for or magnitude of a presently unforeseen one-time restructuring expense or the values of end-of-period foreign currency exchange rates. As a result, Catalent does not believe that a U.S. GAAP reconciliation would provide meaningful supplemental information about its outlook.

Use of Constant Currency

As changes in exchange rates are an important factor in understanding period-to-period comparisons, Catalent believes the presentation of results on a constant-currency basis in addition to reported results helps improve investors’ ability to understand its operating results and evaluate its performance in comparison to prior periods. Constant-currency information compares results between periods as if exchange rates had remained constant period over period. Catalent uses results on a constant-currency basis as one measure to evaluate its performance. Catalent calculates constant currency by calculating current-year results using prior-year foreign currency exchange rates. Catalent generally refers to such amounts calculated on a constant-currency basis as excluding the impact of foreign exchange or being on a constant-currency basis. These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. GAAP. Results on a constant-currency basis, as Catalent presents them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP.

Forward-Looking Statements

This release contains both historical and forward-looking statements. All statements other than statements of historical fact, are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “project,” “predict,” “hope,” “foresee,” “likely,” “may,” “could,” “target,” “will,” “would,” or other words or phrases with similar meanings. Similarly, statements that describe Catalent’s objectives, plans, or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: the current or future effects of the COVID-19 pandemic or any global health developments on Catalent's or its customers' or suppliers' businesses; participation in a highly competitive market and increased competition that may adversely affect Catalent’s business; demand for its offerings, which depends in part on its customers’ research and development and the clinical and market success of their products; product and other liability risks that could adversely affect Catalent’s results of operations, financial condition, liquidity and cash flows; failure to comply with existing and future regulatory requirements; failure to provide quality offerings to customers could have an adverse effect on Catalent’s business and subject it to regulatory actions and costly litigation; problems providing the highly exacting and complex services or support required; global economic, political and regulatory risks to Catalent’s operations; inability to enhance existing or introduce new technology or service offerings in a timely manner; inadequate patents, copyrights, trademarks and other forms of intellectual property protections; fluctuations in the costs, availability, and suitability of the components of the products Catalent manufactures, including active pharmaceutical ingredients, excipients, purchased components and raw materials; changes in market access or healthcare reimbursement in the United States or internationally; fluctuations in the exchange rate of the U.S. dollar against other currencies; adverse tax legislative or regulatory initiatives or challenges or adjustments to Catalent’s tax positions; loss of key personnel; risks generally associated with information systems; inability to complete any future acquisition or other transaction that may complement or expand its business or divest of non-strategic businesses or assets and difficulties in successfully integrating acquired businesses and realizing anticipated benefits of such acquisitions; risks associated with timely and successfully completing, and correctly anticipating the future demand predicted for, capital expansion projects at existing facilities; offerings and customers’ products that may infringe on the intellectual property rights of third parties; environmental, health, and safety laws and regulations, which could increase costs and restrict operations; labor and employment laws and regulations or labor difficulties, which could increase costs or result in operational disruptions; additional cash contributions required to fund Catalent’s existing pension plans; substantial leverage that may limit its ability to raise additional capital to fund operations and react to changes in the economy or in the industry; and exposure to interest-rate risk to the extent of its variable-rate debt preventing it from meeting its obligations under its indebtedness. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in Catalent’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021, filed August 30, 2021. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent does not undertake to update any forward-looking statement as a result of new information or future events or developments except to the extent required by law.

More products. Better treatments. Reliably supplied.™

Чистая выручка за 3'22 квартал в размере 1,27 миллиарда долларов увеличилась на 21%, как сообщалось, или на 23% в постоянной валюте, по сравнению с 3'21 кварталом. Органическая чистая выручка в постоянной валюте выросла на 20% по сравнению с 3 кварталом 21 года.

Чистая прибыль за 3'22 квартал составила 141 миллион долларов.

Скорректированная EBITDA(1) за 3'22 квартал в размере 339 миллионов долларов увеличилась на 24%, как сообщалось, или на 26% в постоянной валюте, по сравнению с 3'21 кварталом.

Увеличение и ужесточение руководства на 22 финансовый год с учетом прогнозируемого роста чистой выручки на 20-23% и скорректированного роста EBITDA на 24-28% по сравнению с предыдущим прогнозируемым ростом чистой выручки на 19-22% и скорректированным ростом EBITDA на 23-27%.

Предварительный прогноз органического роста чистой выручки в постоянной валюте на 23 финансовый год в соответствии с долгосрочными темпами роста на 8-10%.

СОМЕРСЕТ, Нью-Джерси - (BUSINESS WIRE) - Catalent, Inc. (NYSE: CTLT), мировой лидер, позволяющий фармацевтическим, биотехнологическим и потребительским партнерам оптимизировать разработку, запуск и поставку более качественных методов лечения пациентов с использованием различных методов, сегодня объявила финансовые результаты за третий квартал 2022 финансового года, который закончился 31 марта 2022 года.

“Мы довольны нашими высокими результатами в третьем квартале и нашими планами продолжать расширять наши возможности для удовлетворения долгосрочных потребностей клиентов по мере роста наших конечных рынков. Наши недавние приобретения в области клеточной терапии в США и производства биологических препаратов в Великобритании, а также недавно одобренные инвестиции в размере 350 миллионов долларов в Блумингтоне, штат Индиана, обеспечат дополнительные гибкие возможности и позволят нам поставлять все большее количество продуктов и методов лечения пациентам и потребителям по всему миру”, - сказал Джон Чимински, председатель и главный исполнительный директор Catalent, Inc.

Консолидированные результаты за Третий квартал 2022 года

Чистая выручка в размере 1,27 миллиарда долларов увеличилась на 21%, как сообщалось, или на 23% в постоянной валюте, по сравнению с 1,05 миллиарда долларов, о которых сообщалось за третий квартал год назад. Общий органический рост чистой выручки (т.е. без учета эффекта приобретений, продажи и пересчета валют) составил 20% за те же периоды.

Чистая прибыль, приходящаяся на обыкновенных акционеров, составила 141 миллион долларов, или 0,78 доллара на базовую и 0,78 доллара на разводненную акцию, по сравнению с чистой прибылью, приходящейся на обыкновенных акционеров в размере 217 миллионов долларов, или 1,27 доллара на базовую акцию, 1,26 доллара на разводненную акцию, в третьем квартале год назад, снижение, вызванное частично за счет прибыли в размере 184 миллионов долларов от продажи бизнеса по производству выдувных пломб в предыдущем году.

Показатель EBITDA от операционной деятельности(1) составил 308 миллионов долларов, что на 112 миллионов долларов меньше, чем 420 миллионов долларов в третьем квартале прошлого года, что частично обусловлено прибылью в размере 184 миллионов долларов от продажи бизнеса по производству выдувных пломб в предыдущем году. Скорректированная EBITDA за третий квартал 2022 финансового года(1) составила 339 миллионов долларов, или 27% от чистой выручки, по сравнению с 274 миллионами долларов, или 26% от чистой выручки, в третьем квартале год назад. Это представляет собой увеличение на 24%, как сообщалось, и увеличение на 26% в пересчете на постоянную валюту по сравнению с периодом 2021 финансового года.

Скорректированная чистая прибыль(1) составила 188 миллионов долларов, или 1,04 доллара на разводненную акцию, по сравнению с скорректированной чистой прибылью в размере 148 миллионов долларов, или 0,82 доллара на разводненную акцию, в третьем квартале год назад.

Обзор сегмента за Третий квартал 2022 года